Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Journal of clinical oncology, 2020-09, Vol.38 (27), p.3138-3149 [Peer Reviewed Journal]2020 by American Society of Clinical Oncology 2020 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.20.00147 ;PMID: 32678716
Full text available